Latest for Galactosemia
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
- Trial statusNo longer enrolling. Early Check: Expanded Screening in Newborns (RTI International)ClinicalTrials.gov
More about Galactosemia
Manifestations appear within days to weeks after birth in fed infants: cataracts develop as galactose is shunted into the aldose reductase pathway, producing galactitol which accumulates in the lens causing osmotic stress and lens opacification ("oil drop" cataracts visible in first week of life). Liver dysfunction and jaundice appear within the first 1-2 weeks; hepatomegaly, elevated transaminases, and coagulopathy indicate liver involvement. Intellectual disability develops progressively without early intervention, with permanent cognitive impairment by 6-12 months if diagnosis is delayed.
Keep reading about Galactosemia
Ovarian failure is a significant and poorly preventable complication even with adequate treatment, affecting approximately 80% of females treated from infancy; accelerated ovarian aging and depletion of oocytes occurs due to galactose-1-phosphate toxicity to primordial follicles. Newborn screening has dramatically improved outcomes by enabling early diagnosis and dietary intervention.
What are the symptoms of Galactosemia?
These are common symptoms of Galactosemia, and how strong they are varies from person to person.
- Cataracts developing in first days to weeks
- Feeding difficulty and poor weight gain
- Vomiting and diarrhea
- Jaundice and hepatomegaly
- Intellectual disability if untreated
- Ovarian failure in females
Who gets Galactosemia?
Galactosemia shows autosomal recessive inheritance, affecting males and females equally across all ethnic populations. However, significant geographic variation in prevalence occurs based on GALT gene variant distribution: highest in populations of African descent (approximately 1 in 30,000-40,000) and Caucasian populations (approximately 1 in 60,000); lower in Asian populations (approximately 1 in 100,000).
Manifestations appear in neonates and early infants as galactose accumulation occurs following feeding (breast milk or formula containing lactose). Symptoms typically appear within the first days to weeks of life. Variant galactosemia forms (transferase deficiency, UDP-galactose-4-epimerase deficiency) show different phenotypes with less severe manifestations; newborn screening identifies classical galactosemia preferentially. Carrier frequency is approximately 1 in 70-150 depending on population. Recurrence risk for siblings is 25% per pregnancy if both parents are confirmed carriers.
Next steps: find trials you might fitsee what is being testedget help payingget alerts
Side effects people have reported to the FDA
Side effects people have reported to the FDA
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Diagnosis and genetic testing
Genetic testing for Galactosemia
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted Galactosemia resources
Reputable organizations and medical references for learning more about Galactosemia, including disease registries, foundation resources, and clinical guidelines.